BridgeBio Pharma, Inc. recently announced that interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints, with expanded results to be presented ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc.

CEO Neil Kumar outlined the company’s recent clinical progress, commercial momentum, and near-term regulatory plans during a ...

Late-Breaking Oral Presentation: Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints Presenter: Katherine Mathews, M.D., Professor of ...

If you are trying to work out whether BridgeBio Pharma's recent share price puts it at an attractive entry point or not, you will want to look past the headlines and focus on what the underlying value ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.95 EPS, expectations were $-0.88.

BridgeBio Pharma (NASDAQ: BBIO) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today ...

BridgeBio Pharma shares have fallen 11% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $68.31, a climb of 88% in the last 12 months.

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the ...